Related Experiment Video
Updated: May 5, 2026

08:20
MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
Published on: August 11, 2015
14.5K
Case Report: Personalizing Transcranial Magnetic Stimulation Therapy for Treatment-Resistant Depression for a Patient
Julia C Schmidt1, Rachel Davis2, Erica Rapp2
1From University of San Diego School of Medicine (Ms. Schmidt).
Harvard Review of Psychiatry
|January 2, 2026
Summary
This case report shows that transcranial magnetic stimulation (TMS) can be safely used in patients with treatment-resistant depression (TRD) and complex medical conditions. Personalized care planning is key to expanding access to neuromodulation treatments.
Area of Science:
- Neurology
- Psychiatry
Background:
- Treatment-resistant depression (TRD) presents challenges due to complex medical comorbidities.
- Existing guidelines for transcranial magnetic stimulation (TMS) lack specificity for managing high-risk patients.
- Clinicians face difficulties in determining TMS candidacy and risk management for medically complex individuals.
Purpose of the Study:
- To detail the safe and effective use of TMS in a medically complex patient with severe TRD.
- To highlight the role of interdisciplinary care coordination in managing such cases.
- To emphasize personalized treatment planning for neuromodulation access.
Main Methods:
- A case report of a 49-year-old male with major depressive disorder and comorbidities including chronic pain, hypocalcemia, and basal ganglia calcifications.
- Illustrates interdisciplinary care coordination for TMS administration.
- Focuses on personalized risk assessment and management strategies.
Main Results:
- Successfully administered TMS to a medically complex patient with severe TRD.
- Demonstrated the feasibility of safe and effective neuromodulation in a challenging clinical scenario.
- Showcased the benefit of a coordinated, individualized approach.
Conclusions:
- Interdisciplinary care coordination enables safe and effective TMS use in medically complex TRD patients.
- Personalized treatment planning is crucial for expanding access to neuromodulation.
- This case supports TMS as a viable option for select high-risk TRD patients.
Keywords:
Graves’ diseaseTMShypocalcemiahypoparathyroidismpersonalized treatment-resistant depressiontranscranial magnetic stimulationMore Related Videos
Related Concept Videos
Psychosis: Goals of Pharmacotherapy
706
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
706
Antidepressant Drugs: MAOIs and Other Agents
1.3K
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.3K
Drug Therapy
449
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
449
Electroconvulsive Therapy
2.6K
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
2.6K

